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Review TRENDS in Parasitology Vol.23 No.10Open access under CC BY license.So-called ‘neglected tropical diseases’ (NTDs) are
becoming less neglected, with increasing political and
financial commitments to their control. These recent
developments were preceded by substantial advocacy
for integrated control of different NTDs, on the premise
that integration is both feasible and cost-effective.
Although the approach is intuitively attractive, there
are few countrywide experiences to confirm or refute this
assertion. Using the example of Uganda, this article
reviews the geographical and epidemiological bases for
integration and assesses the potential opportunities for,
and operational challenges of, integrating existing con-
trol activities for several of these diseases under an
umbrella vertical programme.
Potential for integration
Greater emphasis is being given to controlling neglected
tropical diseases [NTDs; Neglected tropical diseases, hid-
den successes, emerging opportunities (http://whqlibdoc.
who.int/hq/2006/WHO_CDS_NTD_2006.2_eng.pdf)]. The
term ‘NTDs’ is used because they exclusively affect the poor
and marginalized in low-income countries and, until
recently, received little or no advocacy or funding. Themost
important African NTDs are shown in Table 1. Although
these diseases are thought to kill up to 500 000 people per
year [1], mortality figures alone do not capture the main
impact of NTDs on public health, which largely arises from
chronic disability andmorbidity [2]. In an effort to control or
eliminate this diseaseburden, several global vertical initiat-
ives have been established [3]. Since 2004, there has been
greater advocacy for the logistical and economic benefits of
integrated control of NTDs, whereby different treatment
strategies are bundled together [4–6]. Integration can also
involve another aspect: linking intervention packages with
ongoing healthcare delivery [7].
Small-scale efforts to integrate vertical NTD pro-
grammes have been undertaken in several African
countries. For example, in Nigeria, integrated distribution
of anthelmintic treatments combinedwith insecticide-trea-
ted nets (ITNs) by community-based volunteers resulted inCorresponding author: Kolaczinski, J.H. (j.kolaczinski@malariaconsortium.org).
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coverage of mass drug administration (MDA) [8]. To help
support national programmes, the World Health Organ-
ization (WHO) has recently published guidelines on inte-
grated helminthiasis control, which have been designed
to deal with drugs and their coordinated use in all epi-
demiological situations, including those in which there is
limited geographical overlap [Preventive chemotherapy
in human helminthiasis (http://whqlibdoc.who.int/
publications/2006/9241547103_eng.pdf)]. In addition,
the Global Network for Neglected Tropical Disease Con-
trol was launched in October 2006, with the aim of
providing advocacy and coordinating the efforts of
NTD-control partners [9]. However, although the
concept of integration is logistically and economically
appealing, experience at the country level is surprisingly
limited.
Similar to many other developing countries, Uganda
is affected by a high burden of NTDs: visceral leishma-
niasis (VL; kala-azar) [10], human African trypanosomia-
sis (HAT) [11], trachoma [12], Buruli ulcer [13],
soil-transmitted helminths (STHs) [14], schistosomiasis
owing to Schistosoma mansoni [15], lymphatic filariasis
(LF) [16] and onchocerciasis [17] (Table 2). Dracunculia-
sis and leprosy have recently been eliminated from
the country [18]. Uganda provides a useful insight into
the control of NTDs because it is one of the few African
countries that has undertaken nationwide assessments
for several NTDs [15–17] and already piloted integrated
control [19]. It also implements a broader integrated
health package through the Child Health Days (CHDs)
instigated by the Ministry of Health (MoH) and is one of
five African ‘fast-track’ countries that receives support
from the US Agency for International Development
(USAID), to develop an integrated NTD control pro-
gramme [RTI launches integrated program to address neg-
lected tropical diseases (http://www.rti.org/newsroom)].
Implementation of such a package necessitates careful
consideration of several issues, including the geography,
epidemiology and ecology of different NTDs, in addition
to the advantages and disadvantages of existing control
strategies.07.08.007
Table 1. NTDs and their control in Africa
Disease Aetiologic agent Distribution Control strategy Drugs International programmes
Helminth
STHs Ascaris
lumbricoides
A. lumbricoides and
T. trichiura
restricted to
equatorial
regions; hookworm
is widespread
Annual mass
treatment of
schoolchildren and
whole communities
in high-prevalence
areas
Benzimidazole
anthelmintic
treatments,
albendazole and
mebendazole
Mebendazole donation initiative
supported by Johnson and Johnson
(http://www.taskforce.org/mebendazole)Trichuris
trichiura
Hookworm
Schistosomiasis
(bilharziasis)
Schistosoma
haematobium
Africa-wide Annual mass
treatment of
schoolchildren and
whole communities
in high-prevalence
areas
Praziquantel Schistosomiasis control
initiative
(http://www.schisto.org)S. mansoni
LF
(elephantiasis)
Wuchereria
bancrofti
Endemic in 39
African countries
Annual MDA to
treat the entire
population for a
(currently
undefined) long
period, to interrupt
transmission
Albendazole and
ivermectin
Global Alliance for the
Elimination of Lymphatic
Filariasis
(http://www.filariasis.org)
Onchocerciasis
(river
blindness)
Onchocerca
volvulus
Endemic in 30
African countries
Vector control
through spraying
of larvicides and
annual CDTI
Ivermectin African Programme for
Onchocerciasis Control
(http://www.Apoc.bf/en/)
Dracunculiasis
(Guinea
worm)
Dracunculus
medinensis
Eliminated as a
public health
problem
Active case
detection,
provision of a
water supply and
use of cloth filters
Guinea worm eradication
programme
(http://www.cartercenter.org/
health/guinea_worm/index.html)
Protozoan
Cutaneous
leishmaniasis
Leishmania
tropica
Scattered foci
throughout Africa
Case detection
and treatment.
Personal
protection
through use of
mosquito nets
Pentavalent
antimonial
treatments; the
second-line drug
is amphotericin
Leishmania major
Leishmania
infantum
VL (kala-
azar)
Leishmania
donovani
Scattered foci in
the Horn of
Africa, Sudan,
Ethiopia,
Somalia, Kenya
and Uganda
Case detection
and treatment.
Personal
protection
through use of
mosquito nets
Pentavalent
antimonial
treatments; the
second-line drug
is amphotericin
Drugs for Neglected Diseases
initiative
(http://www.dndi.org/)
HAT T. b. gambiense Endemic in 37
African countries
Case detection
and treatment.
Vector control
through spraying,
traps and targets
T. b. rhodesiense:
suramin or
melarsoprol in
early- or late-
stage disease,
respectively
Programme against African
trypanosomiasis
(http://www.fao.org/ag/againfo/
programmes/en/paat/home.html)
T. b. rhodesiense
T. b. gambiense:
pentamidine or
suramin for early-
or late-stage
disease, respectively.
The alternative
for melarsoprol-
refractory late-
stage T. b.
gambiense
treatment is
eflornithine
Bacterial
Trachoma Chlamydia
trachomitis
Widespread
throughout the
continent
Surgery,
antibiotic
therapy, facial
cleanliness and
environmental
improvement
(SAFE) strategy
Zithromax International trachoma
initiative
(http://www.trachoma.org)
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Table 1 (Continued )
Disease Aetiologic agent Distribution Control strategy Drugs International programmes
Buruli ulcer Mycobacterium
ulcerans
Reported cases
from eight west
African
countries, seven
central Africa
countries, Malawi
and Uganda
Case detection,
treatment and
surgery
Rifampicin and
streptomycin or
amikacin
Leprosy Mycobacterium
leprae
Close to
elimination
(defined as
prevalence of <1
case per 10 000
population),
although pockets
of high
endemicity remain
in several areas
of Angola, the
Central African
Republic, the
Democratic
Republic of
Congo, Madagascar
and Tanzania
Multidrug therapy Dapsone and
rifampicin
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Understanding which geographical areas require
intervention is fundamental for cost-effective disease con-
trol. NTDs in Uganda have been mapped using a variety of
survey methodologies. The distribution of onchoceriasis
has been estimated using the rapid epidemiological
mapping of onchoceriasis (REMO) method [20], enabling
communities to be classified into three categories: priority
areas requiring community-directed drug treatment with
ivermectin (CDTI); areas not requiring treatment; and
possible endemic areas requiring further investigation
[17]. Rapid mapping of LF included school surveys usingTable 2. NTDs in Uganda
Disease Distributiona
A. lumbricoides and T.
trichiura
Unevenly distributed; the highest
prevalence is in southwest Uganda
Hookworm Throughout Uganda (the prevalence is low
in the northeast)
Schistosomiasis In 30 districts, particularly near the
shores of lakes Albert and Victoria and
along the Albert Nile
LF North of the Victoria Nile and in west
Uganda
Onchocerciasis In 27 districts; highly endemic in the west
Nile region, central shores of lake Albert,
Mount Elgon and foci in southwest Ugand
Dracunculiasis Eliminated as a public health problem
VL Pokot county and the Nakapiripirit district
(northeast Uganda)
HAT Northwest Uganda, predominantly in the
Adjumani, Moyo, Arua and Yumbe district
Southeast and east Uganda
Trachoma In 15 districts (according to HMIS
records); a nationwide survey is planned
Buruli ulcer Unknown
Leprosy Eliminated as a public health problem
aThe number of districts quoted here and elsewhere in the document refers to the num
districts.
bGLRA/NTPL. Leprosy Status Report 2004. German Leprosy Relief Association/National
www.sciencedirect.comimmunochromatographic antigenic detection cards and
the application of geostatistical methods to create a nation-
wide estimation of the prevalence of LF [16]. The distri-
butions of schistosomiasis and STH infections were defined
according to nationwide parasitological surveys [14,15].
More recently, rapid mapping of schistosomiasis used lot
quality-assurance sampling (LQAS) to finely target control
[21]. LQAS has also been used to estimate the prevalence of
Trypanosoma brucei gambiense trypanosomiasis in north-
ern Uganda, enabling communities to be ranked according
to prevalence categories [22]. Elsewhere, distributions of
HAT have been assessed using expensive case detection byNationwide burden Refs
Average prevalence of <10%, but >50% in
southwest Uganda
[14]
er Prevalence of >50% [14]
About 4 million cases; 16.7 million are
at risk
[15]
Prevalence of circulating filarial
antigens in schoolchildren is 0.4–30.7%;
13.9 million are at risk
[16]
a
Greater than 2 million at risk; 1.36
million infected
[17]
Eliminated [18]
Unknown; >600 cases treated per year, of
which 70% are from Kenya
[10]
s
In 2005, 267 cases were reported
In 2005, 479 cases were reported [11,24]
Unknown [12]
Unknown
In 2004, 2.5 new cases per 100 000
population
b
ber prior to recent administrative changes that have divided some of the previous
TB and Leprosy Programme. Wandegeya, Kampala, Uganda, 2004.
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occurs in northwestern Uganda, whereas Trypanosoma
brucei rhodesiense has traditionally occurred in southeast-
ern areas [23]. These two foci are currently geographically
separated but are becoming worryingly close [11,24]. The
endemicity of VL has, so far, been defined only on the basis
of passive case-detection data, which suggest that the
disease is restricted to Pokot county, a semiarid lowland
area in the Nakapiripirit district [10]; however, there are
concerns that VL might be endemic over a larger area.
Trachoma is thought to be endemic in at least 26 districts,
putting 7 million people at risk. A nationwide survey is
planned, to provide detailed data on the distribution and
burden of trachoma.
On the basis of these geographical assessments, it is
possible to qualitatively define the codistribution of differ-
ent NTDs (Figure 1). Existing data indicate that oncho-
cerciasis, schistosomiasis and LF are coendemic in ten
districts of northwesternUganda, putting>500 000 people
at risk of coacquiring them. LF is coendemic with schisto-
somiasis in at least 19 districts and with onchocerciasis inFigure 1. Areas of Uganda endemic or coendemic for NTDs that are controlled us
schistosomiasis, light green areas are endemic for onchocerciasis, yellow areas are e
counties (administrative areas below district level) coendemic for schistosomiasis an
coendemic and dark green areas are districts in which schistosomiasis, LF and onchoc
www.sciencedirect.comat least 13 districts. Further surveys are required to
confirm whether coendemicity applies to whole districts
or is more localized.
Epidemiology and ecology of integrated control
Control of different NTDs must be based on a detailed
understanding of their epidemiologies and modes of para-
site transmission. The target age-groups might differ be-
tween NTDs [4]. The prevalence and intensity of
schistosomiasis and STHs (except hookworm) are greatest
among school-age children or young adults and decrease
throughout adulthood [15,25], whereas for LF and hook-
worm age-specific prevalence rises throughout childhood
and attains a stable asymptote, or rises marginally, in
adulthood [26–28]. Epidemiological patterns of onchocer-
ciasis vary markedly between geographical zones [29]; in
Uganda, the prevalence of infection increases throughout
childhood and reaches a plateau at 20 years, whereas the
occurrence of nodules and onchocercal dermatitis increases
throughout childhood and adulthood [30,31]. Thus, school-
age children are the natural targets for population-baseding MDA of preventative chemotherapy. Areas shown in red are endemic for
ndemic for VL and light blue areas are endemic for LF. Dark blue areas indicate
d onchocerciasis, orange areas are districts in which schistosomiasis and LF are
erciasis are present. STHs are endemic throughout Uganda.
Review TRENDS in Parasitology Vol.23 No.10 489treatment of STHs and schistosomiasis, whereas
communitywide treatment is warranted for LF and
onchocerciasis.
LF and onchocerciasis are vector-borne diseases,
transmitted by several genera of mosquitoes and blackflies
of the Simulium genus, respectively. Vector control has
been highly effective in the control of onchocerciasis [32],
for which the stated goal is interruption of transmission,
andmight potentially have a significant role in elimination
of LF [33]. In both cases, communities within whole
districts should be targeted with interventions [34,35].
Transmission of STHs and schistosomiasis depends on
contamination of soil and snail-infested water with human
faeces and urine, hindering elimination in settings with
inadequate water supply and sanitation. Consequently,
the goal of schistosomiasis and STH control is the
reduction of morbidity, hence interventions typically
target age-groups with the greatest morbidity, namely
school-age children and young adults in high-prevalence
communities or subdistricts [36,37]. These different treat-
ment goals and intervention units require consideration in
the design of integrated treatment programmes for NTDs.
HAT is transmitted by tsetse flies and occurs more often
in adults [38], whereas VL is transmitted by sandflies and,
at least in Uganda, is most common in children and teen-
agers [10]. Vector control can make an important contri-
bution to reducing the burden of both diseases [39–41], but
it is rarely implemented because of a lack of financial
resources. Treatment is lengthy, expensive and relatively
toxic. Development of new drugs and adequate diagnostic
tools has been slow [42,43], although a reliable rapid
diagnostic test for VL is now available [44].
Current control of neglected tropical diseases in
Uganda
The control of most NTDs is the mandate of the Vector
Control Division (VCD) of the Ugandan MoH. The VCD
was established in the early 1920s and led national vector-
borne disease control until the 1970s, when it virtually
collapsed during military rule, only being rehabilitated in
1994 [45].
The longest-running control programme in the VCD is
the national onchocerciasis control programme, estab-
lished in 1992. Since the mid-1990s, it has been supported
by the Carter Centre’s Global 2000 River Blindness Pro-
gramme, Sight Savers International, the Gesellschaft fu¨r
Technische Zusammenarbeit and the African Programme
for Onchocerciasis Control. Intervention consists of annual
CDTI, supplemented by vector control in isolated foci of
Simulium neavei [46,47]. To date, geographical treatment
coverage has reached 100% and therapeutic coverage
remains stable at 80%. Large-scale vector control is unfea-
sible because the breeding sites are too widespread or
inaccessible and extend into politically unstable countries,
such as the Democratic Republic of Congo.
The cornerstone of LF control is annual MDA of a single
dose of ivermectin and albendazole, provided to the entire
‘at-risk’ population in targeted districts. The first MDA for
LF was carried out at the end of 2002 in two districts with
a total population of 1 million people, reaching 75%
coverage. Scaling up the programme to cover eightwww.sciencedirect.comadjacent districts, planned for 2003, was delayed because
of insecurity and insufficient operational funds. In 2004,
MDAwas carriedout infivedistricts,witha total population
of>2million, and, in 2005, the programme was extended to
cover ten districts, with a total population of 4.9 million. In
2006 no distribution took place, owing to a lack of funds for
drug delivery. MDA is carried out in schools and commu-
nities by trained teachers and community drug distributors
(CDDs), respectively, with most districts having reached at
least 65% coverage. It is increasingly appreciated that the
use of ivermectin and albendazole in MDA for the elimin-
ation ofLFhas ancillary benefits against onchocerciasis and
STHs [4].
For the combined control of schistosomiasis and STH
infections, a national programme was established in 2003
[48], with support from the Schistosomiasis Control
Initiative. The programme is managed centrally by the
VCD, but it is implemented by district health teams. MDA
of praziquantel and albendazole is provided to all school
children in target subcounties (at the subdistrict level) and
the whole community in areas where prevalence of in-
fection exceeds 50%. Treatment is carried out by teachers
and CDDs in schools and communities, respectively [49].
HAT control activities, consisting of the mass treatment
of livestock using trypanocides and vector control,
were implemented in parts of the Soroti district between
January 2000 and December 2003. However, a survey
conducted in 2004 of Soroti markets showed a high preva-
lence of T. b. rhodesiense in cattle bought from areas in
southeast Uganda with endemic sleeping sickness. This
showed that control activities have been largely ineffective,
and the trade and resultant movement of animals infected
with trypanosomes continues [11]. Currently, no control is
undertaken against VL, Buruli ulcer or trachoma.
Progress and prospects of integrated control
The feasibility study of integrating treatment for
onchocerciasis with schistosomiasis and STH infections
showed that the treatment coverage of ivermectin, prazi-
quantel and mebendazole were increased using the inte-
grated approach [19]. An identified disadvantage was that
supplies of praziquantel and mebendazole ran out more
frequently, because treatmentswere being administered to
nontarget groups. The investigators suggested that the
CDDs might have thought that they or their immediate
relatives had schistosomiasis and/or STH infections, and
thus treated themselves or their family before treating the
targeted high-risk groups in the neighbourhood. Despite
the promising results, integration has not been put into
practice to date, although financial support from the
USAID aims to expand integrated delivery of anthelmintic
treatment from 2007.
STH control also forms one of the components of the
CHDs in Uganda, which take place twice each year (in
April and October). CHDs are a period of accelerated
routine maternal and child health interventions, delivered
at all static health units and through outreach in commu-
nities and schools. The package of interventions includes
vitamin A supplementation, childhood vaccination and
promotion of hygiene at home and school. Implementation
is through a multidisciplinary team of health workers,
490 Review TRENDS in Parasitology Vol.23 No.10community members (including CDDs), vaccinators and
mobilizers. The provision of annual albendazole treatment
by this integrated approach improves the nutritional sta-
tus of young children [50].
The strategy proposed for integrated control of LF,
onchocerciasis, schistosomiasis, STHs and trachoma, to be
supported by the USAID, focuses on the integration of
individual drug-delivery activities under an umbrella pro-
gramme, to provide simultaneous, or almost simultaneous,
population-based treatment. Only four drugs – albendazole,
ivermectin, praziquantel and azithromycin – are used to
control seven major NTDs – schistosomiasis, hookworm,
trichuriasis, ascariasis, trachoma, LF and onchocerciasis.
These NTDs exhibit considerable geographical overlap [1],
at least if viewed at the country level [6]. It is thus thought
that a single structure, such asCDTI, CHDs or theNational
MalariaControlProgramme, couldbereadilyused todeliver
more than one treatment. Because the structures are
already in place, this would, in theory, only slightly increase
costs if a component isaddedor reducecosts if twostructures
are merged, while considerably expanding coverage
[4,6,51,52]. In Uganda, however, there is a limited geo-
graphical overlap between the different NTDs (Figure 1),
necessitating a more geographically targeted approach.
Furthermore, the structural changes required to deliver
an integrated package are still being undertaken. In the
interim, it is already planned that the LF programme will
provide ivermectin inApril each year and the onchocerciasis
control programme will provide ivermectin in October each
year. In areas coendemic for LF and onchocerciasis, such an
approach has the potential to eliminate both diseases
[53,54].
In addition to differences in delivery structure and
target geographical areas, the frequency of drug adminis-
tration varies between control programmes. Treatment for
STHs is recommended every 6–12 months, whereas treat-
ment for onchocerciasis and LF is recommended annually.
The actual frequency and number of rounds of ivermectin
treatment required to interrupt transmission of LF or
onchocerciasis are unknown [29]. Although schistosomia-
sis treatment using praziquantel is currently provided
annually, longer treatment intervals might become justi-
fied as infection levels decrease. Coordinating these differ-
ent treatment intervals represents a challenge for
integration.
Treatment regimens for HAT and VL are too toxic and
lengthy to be delivered outside a health facility [23,42,55]
and are thus unsuitable for inclusion in this new inte-
grated approach. A threat exists, therefore, that control of
HAT, VL and other NTDs will continue to be neglected, as
attention is focused on diseases that have a population-
based chemotherapy strategy. Recent NTD advocacy has
contributed to the allocation of funds for the development
of a new generation of control tools (drugs, diagnostics
and vaccines) for VL and HAT, in addition to other NTDs
[e.g. the Drugs for Neglected Diseases initiative (http://
www.dndi.org) and Sabin Vaccine Institute (http://www.
sabin.org)], but has had little impact on the allocation of
funds to deliver existing HAT and VL control tools. Until
new tools become available, control with existing, although
imperfect, tools must be intensified [42,56].www.sciencedirect.comIn addition to integrating treatment, there is
considerable potential for integrated vector control for
several NTDs, which receives little mention. In Uganda,
the same mosquito species transmit both LF and malaria
in the same districts [26]. Increasing the coverage with
long-lasting ITNs (LLINs), as part of the malaria control
efforts, is thus likely to impact on LF vector densities and
transmission [57,58] and merits further investigation
[Roles of vector control and xenomonitoring in LF elimin-
ation (http://whqlibdoc.who.int/hq/2002/WHO_CDS_CPE_
PVC_2002.3.pdf)]. Use of LLINs is also likely to provide
personal protection against sandfly vectors of VL [59].
Because VL and malaria are coendemic in Uganda, scaling
up of LLIN coverage in the VL endemic area would be a
good investment in health.
Challenges for integrated control
Approaches for integrated control are still being developed
and best practice will only emerge after experience of
actual implementation. Opportunities for implementation
on a national scale are now being created through the
USAID funding. In designing and implementing country
programmes, several operational challenges exist and inte-
grated control might not be as straightforward and cost-
effective as it is portrayed [Strengthening the potential of
health systems in rural Africa (http://bmj.bmjjournals.com/
cgi/eletters/328/7448/1129)] [60]. Potential shortcomings
include an increased bureaucratic burden, leading to
reduced effectiveness of health services [Health services
are badly needed to control malaria (and other diseases)
(http://bmj.bmjjournals.com/cgi/eletters/328/7448/1129)]
[7]. Also, as the number of interventions increases, the
activities of the CDDs resemble those of a full-time job and
the CDDs cannot attend to other activities that generate
income. The increased workload might prove detrimental
to their performance in any one activity, as already docu-
mented for the onchocerciasis control programme [61], and
lead to demands for incentives in compensation for the
work [62]. Whether, and to what extent, the capacity of
CDDs in Uganda is underused requires further investi-
gation, but it is already apparent that all programmes that
heavily draw on them experience increasing demands for
incentives [63,64]. These demands could, potentially, be
overcome by increasing the number of CDDs so that the
workload of each individual is reduced. However, to
increase the pool of CDDs, more funding would be needed
for training, health education, monitoring and supervision.
The current model of integrated MDA differs from the
more common understanding of integration as ‘a process
where disease control activities are functionally merged or
tightly coordinated with multifunctional health care deliv-
ery’ [7]. Therefore, another challenge is the possibility that
linking vertical control programmes might promote the
development of a parallel health-delivery system, with
separate funding, drugs, delivery channels and staff
[The challenge of global health (http://www.foreignaffairs.
org/20070101faessay86103/laurie-garrett/the-challenge-
of-global-health.html)]. Ideally, drugs should be distr-
ibuted from the centre to health facilities, which then
distribute the drugs to CDDs and schools, as part of their
outreach activities. Health workers should also be involved
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is to be sustainable in the long term and not reliant on
continual donor support, it is essential that interventions
are delivered through existing MoH staff and funded at
national and local levels.
Further challenges are the harmonization of infor-
mation, education and communication (IEC) messages
and their effective delivery. To date, social mobilization
and sensitization of target communities have often been
inadequate, because resources for activities, suchas surveys
of knowledge, attitude and practice, development of IEC
materials and community meetings, were limited. Further-
more, for both the STHand schistosomiasis programmeand
the onchocerciasis control programme, communities were
sometimes not involved in the selection of their CDDs. In
these cases, communities were reluctant to participate in
control activities and CDDs were more likely to ‘drop out’
[63]. These experiences show that resources are urgently
needed to improve on development, implementation and
evaluation of the health-education component of each pro-
gramme and communities must be empowered to select
their own health workers. An integrated approach will face
the same challenges.
The safety and efficacy of certain drug combinations
is also unknown [65]. Combinations currently approved
by the WHO [Preventive chemotherapy in human hel-
minthiasis (http://whqlibdoc.who.int/publications/2006/
9241547103_eng.pdf)] are shown in Table 3. Studies of
coadministration of both ivermectin, albendazole and pra-
ziquantel and anthelmintic treatments and zithromax areTable 3. Summary of approved preventative schedules for helmin
Disease Treatment
LF Treat the entire po
LF and onchocerciasis Treat the entire po
LF and schistosomiasis Round 1: treat the
Round 2 (at least 1
using PZQ
LF and STHs Round 1: treat the
Round 2 (after 6 m
using ALB or MEB
LF, onchocerciasis and
schistosomiasis
Round 1: treat the
Round 2 (at least 1
using PZQ
LF, onchocerciasis and STHs Round 1: treat the
Round 2 (after 6 m
using ALB or MEB
Onchocerciasis Treat the entire po
Onchocerciasis and
schistosomiasis
Round 1: treat the
using IVN
Round 2 (at least 1
using PZQ
Onchocerciasis and STHs Round 1: ALB (tre
in meso- and hype
Round 2 (after 6 m
using ALB or MEB
Schistosomiasis Treat school-age c
Schistosomiasis and STHs Round 1: ALB or M
and adults consid
Round 2 (after 6 m
using ALB or MEB
STHs Round 1: treat sch
Round 2 (after 6 m
using ALB or MEB
ALB, albendazole; DEC, diethylcarbamazine; IVN, ivermectin; MEB, mebendazole; PZQ,
www.sciencedirect.comrequired [60]. Implementation of integrated chemotherapy
that has unknown potential side effects must be accom-
panied by vigorous pharmacovigilance. A general pharma-
covigilance system is currently being put in place in
Uganda, but its implementation already poses numerous
practical challenges [66]. These, and the need for
additional training, monitoring and supervision of health
workers, should limit implementation of an integrated
package to a pilot area and be supported by a strong
operational research component designed to yield the
necessary evidence on safety, effectiveness and operational
constraints [60].
Finally, monitoring and evaluation activities must be
carefully designed and implemented, to answer important
operational questions and modify and support control
packages, as necessary. Guidance on the epidemiological
aspects of evaluating helminth control programmes is
already available [67] and a WHO manual on evaluating
integrated control is currently being developed. However,
evaluation of the health benefits of an integrated control
package represents a major challenge.
Concluding remarks
The success of integrated control depends on a clear
understanding of the distribution and epidemiology of
the diseases to be targeted. In most countries, this infor-
mation is incomplete, requiring detailed surveys to estab-
lish areas of coendemicity and formulate MDA packages
accordingly. With the move towards integrated control,
there is a need to broaden the scope of research, includingthic diseases
pulation at risk using ALB and DEC or ALB and IVN
pulation at risk using ALB and IVN
entire population at risk using ALB and DEC or ALB and IVN
week after Round 1): treat school-age children and adults at risk
entire population at risk using ALB and DEC or ALB and IVN
onths): if the prevalence of STH is 50%, treat school-age children
entire population at risk using ALB and IVN
week after Round 1): treat school-age children and adults at risk
entire population at risk using ALB and IVN
onths): if the prevalence of STH is 50%, treat school-age children
pulation at risk in meso- and hyperendemic communities using IVN
entire population at risk in meso- and hyperendemic communities
week after Round 1): treat school-age children and adults at risk
at school-age children) and IVN (treat the entire population at risk
rendemic communities)
onths): if the prevalence of STH is 50%, treat school-age children
hildren and adults at risk using PZQ
EB (treat school-age children) and PZQ (treat school-age children
ered at risk)
onths): if the prevalence of STH is 50%, treat school-age children
ool-age children using ALB or MEB
onths): if the prevalence of STH is 50%, treat school-age children
praziquantel; LF, lymphatic filariasis; STH, soil-transmitted helminths.
492 Review TRENDS in Parasitology Vol.23 No.10studies of the effectiveness and cost-effectiveness of
integrated control of NTDs compared with existing control
programmes. There is also a need to evaluate the impact of
integration on existing health systems, including the qual-
ity of health care and staffing levels. Efforts to implement
integrated control must be accompanied by investment in,
and strengthening of, healthcare systems and human
resources, because these are prerequisites for the success
of global health initiatives [68].
It is hoped that other health-sector donors will soon
follow the example of the USAID and start to support the
unmet needs for control of NTDs. Resources are urgently
required to establish an evidence base for integrated con-
trol and curb the burden of diseases that cannot be con-
trolled through MDA. Case management of these diseases
must become a functioning component of the existing
healthcare system [56]. Obvious gaps in the Ugandan
context are HAT and VL, which will not benefit from
integrated control as it is currently planned.
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